Please assess the completion status of the following clinical trial:

Trial Title: Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 16 and ≤ 70~* Signed informed consent~* Adequate vital organ function~* No active infection, or asymptomatic infection well controlled by antibiotic HIV negative by ELISA or RT-PCR \[if ELISA is positive and RT-PCR is negative, the ELISA is considered false positive\]~* Hepatitis B and C negative by serology or RT-PCR~* Performance status: Karnofsky Performance Status Score ≥ 60%.~Exclusion Criteria:~* Those with any Sorror's co-morbidity factors with score \> 3~* 2 or more Sorror's factors with composite score of ≥ 3

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus / Rapamycin (TAC/RAPA) (Type: ACTIVE_COMPARATOR): Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Rapamycin: given the day before transplant and continued daily for at least one year.
- Tacrolimus / Methotrexate (TAC/MTX) (Type: ACTIVE_COMPARATOR): Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Methotrexate: given on days 1, 3, 6 and 11, after transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).